CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
neoadjuvant
A collection of 42 issues
CRC Research Update — August 30, 2026
Today's colorectal cancer research highlights
Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer
The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology)
This content is informational
Dual immunotherapy shows promise in mismatch repair proficient colon cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy shows promise in mismatch repair proficient colon cancer
The phase 2 NEST trial tested neoadjuvant botensilimab plus balstilimab in patients with resectable colon cancer. The study examined safety, feasibility, and pathologic response before surgical resection. (Clinical Cancer Research)
This content
CRC Research Update — August 26, 2026
Today's colorectal cancer research highlights
Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery
A phase Ib trial evaluated the safety of combining trifluridine/tipiracil chemotherapy with radiation therapy before surgery in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)
Immunotherapy combinations tested in pMMR/MSS rectal cancer
Skip to content
The CRC Digest
Immunotherapy combinations tested in pMMR/MSS rectal cancer
Meta-analysis evaluates immune checkpoint inhibitor-based neoadjuvant therapy for proficient mismatch repair and microsatellite stable locally advanced rectal tumors. (Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
Always consult your oncologist
Study identifies risk factors for irinotecan liver toxicity
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Study identifies risk factors for irinotecan liver toxicity
A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology)
This content
Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype
Skip to content
The CRC Digest
◆ TRIAL DATA
Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype
A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not
CRC Research Update — August 20, 2026
Today's colorectal cancer research highlights